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Abstract
Human T-cell leukemia virus type 1 (HTLV-1) causes adult T-cell leukemia/lymphoma (ATL) and is
also associated with a variety of lymphocyte-mediated diseases. The HTLV-1 basic leucine zipper
(HBZ) gene, found to be consistently expressed in ATL, has recently been the subject of intensive
research efforts. In this review, we summarize recent findings about HBZ and discuss its roles and
functions not only in the virus life cycle, but also in HTLV-1 disease pathogenesis.
Background
Adult T-cell leukemia/lymphoma (ATL) was proposed as
a distinct clinical entity in 1975 by Takatsuki et al. [1]. An
etiological linkage between ATL and virus infection was
suggested by the geographical clustering of ATL patients in
southwestern Japan. Subsequently, human T-cell leuke-
mia virus type 1 (HTLV-1) was discovered in 1980 as the
cause of ATL and was the first retrovirus associated with a
disease in humans [2,3]. Early focus on the mechanism of
cell transformation has been on the trans-acting viral reg-
ulatory protein Tax. Although studied extensively, the role
of tax in HTLV-1 leukemogenesis remains unclear since
expression of the tax gene as well as other viral genes are
not always detected in ATL cells [4]. More recently, expres-
sion of the HTLV-1 bZIP factor gene (HBZ), an antisense
mRNA transcribed from the 3' LTR, has been shown to be
consistently expressed in ATL cells [5]; thus, HBZ may
have a functional role in cellular transformation and
leukemogenesis.
Expression of HBZ genes in ATL cells and T-cells from 
asymptomatic carriers
Among the HTLV-1 regulatory and accessory genes, the tax
gene is thought to play a central role in leukemogenesis
since it immortalizes T-lymphocytes in vitro, and induces
various cancers in transgenic animals [6,7]. However, an
enigma is that Tax expression is not detected in about 60%
of leukemia cases [4]. Three mechanisms for inactivating
Tax expression in ATL cells have been described: 1) genetic
changes (nonsense mutation, deletion, and insertion) of
the  tax  gene [4,8], 2) deletion of the 5' long terminal
repeat (LTR) containing the viral promoter [9,10], and 3)
DNA methylation of the 5 'LTR leading to promoter inac-
tivation [11,12]. One possible scenario is that since Tax is
the major target of cytotoxic T-lymphocytes (CTL) in vivo
[13], these mechanisms to disrupt or decrease Tax expres-
sion facilitate the escape of ATL cells from host CTL. Inter-
estingly, analyses of HTLV-1 provirus in ATL cells showed
that the 3' LTR was not deleted and remained unmethyl-
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ated. In addition, the pX region (located between env and
the 3' LTR) encoding the regulatory and accessory genes
also is maintained. Detailed analyses of defective provi-
ruses lacking the 5' LTR revealed that all cases maintained
the HBZ gene and the 3' LTR. In one ATL case, the polya-
denylation site of the HBZ gene was deleted [10]; how-
ever, this HBZ  gene utilized a downstream cellular
polyadenylation signal for transcription. Taken together,
these findings suggest that HBZ  gene transcription is
indispensable for the development of ATL.
Two transcripts have been reported that encode the HBZ
gene (Figure 1); one is spliced (sHBZ) and the other is
unspliced (usHBZ) [14,15]. The spliced transcript of the
HBZ gene was first reported by Satou et al. [5], followed
by subsequent reports that additionally identified a sec-
ond minor spliced transcript [14,15]. Furthermore, while
transcripts of the spliced HBZ gene were detected in all
ATL cell lines and cells freshly isolated from ATL patients,
the tax transcript was undetectable in some cell lines and
most ATL cases [5]. Prior to this study, the transcription of
HTLV-1 viral genes in ATL patients was deemed to be
undetectable. Therefore, the HBZ gene is recognized as the
first gene that is uniformly expressed in the leukemic cells
of all ATL patients.
Both sHBZ and usHBZ have TATA-less promoters. sHBZ
has multiple transcriptional initiation sites in the U5 and
R regions of the 3' LTR, whereas the usHBZ gene initiates
within the tax gene. It has been reported that Sp1 is critical
for many TATA-less promoters. Consistent with this, the
transcription of sHBZ gene is dependent on Sp1 [16].
Expression of the sHBZ gene which was detected not only
in ATL cells but also in T-cells of asymptomatic carriers,
appears to be correlated with provirus load [5]. Quantita-
tive analyses of HBZ gene transcripts were reported by two
groups [17,18]. The sHBZ gene transcripts were found to
be four times higher than the usHBZ gene transcripts in
both ATL patients and HTLV-1 carriers [17]. In addition,
the half-life of the sHBZ protein isoform is longer than
that of the usHBZ isoform [16]. Together, the data are
consistent with Western blot analyses of HBZ protein in
ATL cell lines that detected only sHBZ protein [19], fur-
ther supporting the significance of sHBZ protein.
It has been reported that HBZ transcription is correlated
with provirus load [17,18]. As described later, transcrip-
tion of the HBZ gene is dependent on the basal transcrip-
tion factor, Sp1 [16]. Therefore, it is conceivable that the
HBZ transcripts are proportional to provirus load. More
Structure of spliced and unspliced HBZ genes Figure 1
Structure of spliced and unspliced HBZ genes. The U5 and a part of R region of 3'LTR compose the promoter for the 
HBZ gene. The first exon of the spliced HBZ gene corresponds to the region that encodes the Rex responsive element (RxRE). 
The differences in the proteins derived from the spliced and the unspliced HBZ are 4 amino acids in the spliced HBZ and 7 
amino acids in the unspliced HBZ.
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importantly, Saito et al. reported the correlation between
the levels of HBZ gene transcripts and severity of HTLV-1
associated myelopathy/tropical spastic paraparesis
(HAM/TSP), suggesting that HBZ gene expression might
contribute to the pathogenesis of HAM/TSP [18].
Structure of HBZ (the promoter, the coding genes, and the 
protein)
Anti-sense transcription of HTLV-1 was first reported in
1989 [20]. A decade later, the viral protein was detected in
HTLV-1-transformed cell lines and further identified as a
binding protein to CREB2 by the yeast two-hybrid
method. This viral protein bound to CREB2 through its
bZIP domain [21], and was designated as the HTLV-1
bZIP factor (HBZ). 5' rapid amplification of cDNA ends
identified two different HBZ  transcripts: spliced and
unspliced forms (Figure 1) [5,14,15]. The promoter
regions for the spliced and unspliced HBZ transcripts were
identified, and both promoters are TATA-less. Sp1 has
been identified as a critical transcription factor for the
expression of the sHBZ gene [16]. The Tax-response ele-
ment (TRE) motif, which is present in the U3 region of the
LTR, functions as an enhancer of viral sense gene tran-
scription. Tax forms a complex with CREB and p300/CBP,
resulting in marked activation of viral gene transcription.
The TRE in the 3' LTR also functions to enhance transcrip-
tion of the HBZ antisense transcripts [16,22]. However,
the enhancing activity for anti-sense transcription is rela-
tively weak when compared with sense transcription [16].
This is consistent with the finding that transcription of the
HBZ gene is relatively constant in ATL cases regardless of
the variable expression levels of the tax gene [18].
The HBZ protein contains three domains: activation, cen-
tral and bZIP (Figure 2) [21,23]. HBZ binds to host factors
with bZIP domains, which include c-Jun, JunB, JunD,
CREB2 and CREB [24,25]. In addition, HBZ can bind to
the p65 subunit of NF-κB [26]. The HBZ protein is local-
ized in the nucleus with a speckled pattern [27]. Three
regions are associated with nuclear localization: two
regions rich in basic amino acids and a DNA binding
domain (Figure 2). In addition, the integrity of the HBZ
amino acid sequence is necessary for the speckled distri-
bution in the nucleus. HBZ is localized in heterochroma-
tin consistent with its association with transcriptional
inhibition [23] In addition, HBZ has been shown to
sequester JunB into nuclear bodies, thus suppressing
JunB-dependent transcriptional activity [27].
The difference between the sHBZ and the usHBZ isoforms
is only a few amino acids at the N-terminus (Figure 1)
[15]. However, there are notably distinct characteristics.
The half-life of sHBZ is much longer than that of usHBZ
[16]. In addition, the sHBZ mRNA is more predominant
than usHBZ mRNA [17]; thus, the protein level of sHBZ is
much higher than that of usHBZ.
Functional domains of HBZ protein Figure 2
Functional domains of HBZ protein. HBZ has three domains: activation, central and bZIP domains. The interactions with 
host factors and the functions of HBZ are summarized in this Figure.
AD CD bZIP
AD: activation domain
CD: central domain
bZIP: basic ZIP domain
*Inhibition of c-Jun, Jun B (Ref. 24), CREB (Ref. 30), CREB2 (Ref. 21)
*Activation of JunD (Ref. 25) (For this activity, AD is also necessary)
*Interaction with p300 (Ref. 31)
*Binding with p65, inhibition of Canonical NF-NB pathway (Ref. 26)
*Increase of hTERT promoter activity (Ref. 33)
*Binding with 26S proteasome (Ref. 28)
Degradation of c-Jun
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Growth-promoting activity was observed only in a T-cell
line expressing sHBZ, but not in usHBZ-expressing T-cells
[16]. Furthermore, HBZ RNA was shown to have growth
promoting activity [5]. The difference between sHBZ and
usHBZ lies with the presence of the first exon. This region
corresponds to the Rex-responsive element (RxRE) in the
R region of 3'LTR (Figure 1). RxRE forms a tight stem-loop
structure, which is recognized by Rex to facilitate the
nuclear export of viral RxRE-containing RNAs. The oppo-
site strand of spliced HBZ RNA forms a different stem-
loop structure, which might interact with host factors to
induce the proliferation of ATL cells.
Biological differences between sHBZ and usHBZ proteins
have also been demonstrated. usHBZ protein can induce
the degradation of c-Jun in a ubiquitination-independent
manner [28]. usHBZ protein directly interacts with both
the 26 S proteasome and c-Jun, which results in the deliv-
ery of c-Jun to the proteasome. It has been reported that
this activity of sHBZ is much weaker than that of usHBZ.
However, inhibition of AP-1 mediated transcription by
sHBZ was much stronger than that of usHBZ [16]. For the
sHBZ protein, in addition to its higher protein level, its
action to inhibit DNA binding by c-Jun or to sequester c-
Jun in nuclear bodies might represent predominant mech-
anisms of transcriptional suppression.
In vitro functions of HBZ
In vitro studies investigating HBZ functions include both
over-expression studies and those evaluating HBZ in the
context of an infectious viral molecular clone. Initial stud-
ies utilized yeast two-hybrid analysis to show an interac-
tion between HBZ bZIP binding domain and the bZIP
transcription factor CREB2 (ATF-4) (see Figure 3). It was
further shown that this interaction abolished the binding
of CREB2 to the TRE in the HTLV-1 promoter and the
cyclic AMP response element (CRE) in cellular promoters,
consistent with the observations of HBZ dose-dependent
down-regulation of Tax-mediated viral transcription
[21,29]. Other cellular proteins including CREB and
p300/CBP interact with HBZ and contribute to the down-
regulation of Tax-dependent viral transcription [30,31].
However, the interaction of HBZ with p300/CBP is via
two HBZ amino terminal motifs (not the HBZ bZIP
domain) and the p300/CBP KIX domain [31]. HBZ, via its
bZIP domain, also interacts with Jun family members
including JunB, c-Jun, and JunD, thereby modulating
their transcriptional activity [24,25]. Like CREB, HBZ
decreases the DNA binding activity of JunB and c-Jun,
thus disrupting basal transcription of both HTLV-1 and
cellular promoters via attenuation of AP-1 activation (Fos/
Jun dimers) [24,32]. Additional AP-1 transcriptional
repression is explained by HBZ-mediated reduction in c-
Jun stability via the proteasome-dependent pathway, and
sequestration of JunB by HBZ within nuclear bodies
[27,32]. In contrast to JunB and c-Jun, the interaction of
HBZ with JunD stimulates its transcriptional activity and
results in the activation of JunD-dependent cellular genes
including human telomerase reverse transcriptase
(hTERT) [33]. The significance of this finding is that the
activation of telomerase is a critical late event in tumor
progression and that HBZ is the only viral protein
expressed in all ATL cells. Thus, the activation of telomer-
ase by HBZ may contribute to the development and main-
tenance of leukemic cells.
It has been proposed that a highly regulated pattern of
HTLV-1 gene expression is critical for virus-mediated T-
lymphocyte immortalization/transformation and disease
pathogenesis [34]. One study utilized real-time RT-PCR to
determine the kinetics of viral gene expression in cells
transiently transfected with an HTLV-1 proviral plasmid
and in human T-lymphocytes newly infected by virus. The
HTLV-1 gene expression profiles revealed that all sense
and antisense transcripts increased over time and then
plateaued to stable levels. Gag/pol, tax/rex, and env mRNAs
were detected first and at the highest levels, whereas
expression of the accessory genes, including the anti-sense
HBZ, was at significantly lower levels than tax/rex [35].
Arnold et al. evaluated the functional role of HBZ in the
context of an infectious molecular clone and, like other
HTLV-1 accessory gene products, determined that the pro-
tein was dispensable for viral-induced immortalization of
primary human T-lymphocytes [19]. However, a signifi-
cant increase in p19 Gag production was observed in cell
clones expressing HBZ defective proviruses, a finding con-
sistent with the conclusion that in stable cell lines the loss
of HBZ function results in increased Tax-mediated viral
gene expression. Although the inhibition of Tax-mediated
gene expression is a reported function of HBZ, the fact
that HBZ is expressed in ATL cells lacking tax transcripts
suggests that HBZ may have additional functions or activ-
ities. Satou et al. reported that repression of HBZ expres-
sion in ATL cell lines by shRNA resulted in a significant
decrease in cell proliferation [5]. Moreover, shRNA repres-
sion of HBZ  expression in established HTLV-1-trans-
formed cell lines and newly immortalized T-lymphocytes
also significantly suppressed T-lymphocyte proliferation
[19]. Stable expression of HBZ enhanced IL-2-independ-
ent survival of Kit-225 and increased Jurkat cell prolifera-
tive capacity [[5] and Green unpublished]. Introduction
of mutations that either abrogated HBZ protein expres-
sion or disrupted the HBZ mRNA without affecting the
protein coding sequence indicated that the HBZ RNA, spe-
cifically a stem loop structure near the amino terminus of
the gene, promoted T-cell proliferation; this contrasts with
the finding that the HBZ protein inhibited Tax-mediated
transactivation [5]. Thus, these findings led to the conclu-
sion that the HBZ gene has a bimodal function in two dif-
ferent molecular forms. Microarray results and follow up
analyses indicated that transcription of the E2F1 gene and
its downstream targets were up-regulated in HBZ-express-Retrovirology 2009, 6:71 http://www.retrovirology.com/content/6/1/71
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Illustration of the expression and the activities of the HBZ RNA and protein Figure 3
Illustration of the expression and the activities of the HBZ RNA and protein. Viral basal level plus-strand transcrip-
tion is activated by AP-1 (Jun/Fos dimers) which initially favors Tax expression (hooked arrow denotes CAP site). Tax interacts 
with CREB and p300/CBP and the Tax-response element (TRE; 3 black bars in the viral promoter) to transactivate plus-strand 
transcription initially, leading to more Tax expression. Minus strand transcription of HBZ initiates (hooked arrows denote CAP 
sites) at multiple sites in the 3' LTR (sHBZ) and within the tax gene (usHBZ). sHBZ transcription is activated by SP1 with minor 
activation by Tax at the TRE in the 3'LTR. HBZ protein directly interacts with CREB and p300/CBP suppressing Tax-mediated 
plus-strand transcription. HBZ directly binds the Jun family members. Binding to JunB sequesters HBZ into nuclear bodies and 
may promote its proteosomal degradation. HBZ directly binds c-Jun, blocks its DNA binding activity, and facilitates its proteo-
somal degradation. HBZ binding of JunB and c-Jun prevents their interaction with Fos repressing both viral and cellular AP-1 
transcription. HBZ directly interacts with JunD, and in conjunction with SP1 activates JunD-mediated transcription which 
includes the human telomerase reverse transcriptase gene (hTERT). HBZ also interacts with the p65 NFκB subunit, promotes 
its proteosomal degradation, and blocks its interaction with the NFκB p50 subunit resulting in the suppression of the classical 
NFκB transcriptional activation pathway. HBZ mRNA increases the expression of E2F1 which promotes T-lymphocyte prolif-
eration.
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ing cells, suggesting a role for E2F1 in the enhanced pro-
liferation mediated by HBZ [5]. The HBZ RNA, not the
HBZ protein, was shown to be responsible for the up-reg-
ulation of E2F1.
In addition to binding transcription factors containing a
bZIP domain, HBZ has been shown to bind the NF-κB
subunit, p65, and inhibit NF-κB activation. Interestingly,
this inhibition is selective for the classical NF-κB activa-
tion pathway, as the alternate NF-κB pathway is not inhib-
ited [26]. Both the activation and the bZIP domains are
important for the binding of HBZ with the Rel homology
domain of p65 (Figure 2). HBZ not only inhibits DNA
binding by p65, but also promotes the degradation of
p65. As a mechanism of enhanced p65 degradation, HBZ
increases the expression of E3 ubiquitin ligase, PDLIM2,
resulting in ubiquitination and degradation of p65. Thus,
HBZ can suppress the classical NF-κB pathway using two
distinct mechanisms. Other viruses including EBV, Afri-
can swine fever virus, hepatitis C virus, and human her-
pesvirus-8 have also been found to target p65 and inhibit
the classical NF-κB pathway [36].
The classical and alternative NF-κB pathways have distinct
regulatory functions. Accumulating evidence suggests that
the alternative NF-κB pathway is more critical than the
classical pathway in several cancers [37]. The two NF-κB
pathways differentially control genes with anti-apoptotic
functions in lymphoma cell lines [38]. Interestingly,
HTLV-1 Tax is known to activate both the classical and the
alternative NF-κB pathways, and it has been reported that
the alternative pathway is critical to cellular transforma-
tion by Tax [39]. Potentially because HBZ selectively sup-
presses the classical NF-κB pathway, in cells that express
both Tax and HBZ, Tax activity appears to predominantly
activate NF-κB through the alternative pathway.
Recently, PDLIM2 has been reported to suppress Tax-
mediated tumorigenicity by promoting degradation of
Tax [40]. HBZ enhances the expression of PDLIM2 which
should increase the degradation of Tax. Therefore, a com-
plex scenario could exist in which HBZ suppresses Tax
expression at the level of transcription and by enhanced
degradation.
In vivo functions of HBZ
HTLV-1 Tax plays a central role in the immortalization of
T-lymphocytes in cell culture and in the early stages of
leukemogenesis in infected patients. The observation that
HBZ down-modulates Tax function while also promoting
cellular proliferation suggests complex regulations that
could influence viral latency, persistence, and disease.
Although disruption of HBZ protein in an infectious pro-
viral clone had no effect on the ability of the virus to
immortalize T-lymphocytes in tissue culture, the loss of
HBZ did result in a significant reduction of proviral load
and an attenuated antibody response against viral pro-
teins in a rabbit model of infection [29]. As early as two
weeks post infection, the proviral load was reduced 5–50
fold, indicating that the HBZ protein was important very
early in the infection process. Kinetic analysis of viral gene
expression in PBMCs from newly infected rabbits revealed
that tax/rex and gag/pol mRNAs were expressed at the high-
est levels immediately after infection and then progres-
sively declined over time, eventually stabilizing at low
levels [35]. Conversely, HBZ was expressed at a low level
early after infection, and continued to increase before
reaching a plateau, which was in direct correlation with
proviral load levels in infected rabbit PBMCs. These
results revealed an inverse correlation between tax/rex and
HBZ mRNA expression over time, which provided impor-
tant evidence linking HBZ expression to proviral load and
the survival of the virus infected cell in an infected host.
Transgenic mice expressing HBZ under the control of the
mouse CD4 promoter/enhancer displayed an increase in
CD4+ splenic T-lymphocytes suggesting that HBZ pro-
motes proliferation of CD4+ T-lymphocytes in vivo [5].
One transplant tumorigenicity study indicated that
knockdown of HBZ in a transformed T-cell line signifi-
cantly reduced tumor formation and organ infiltration in
NOD/SCIDγchain-/- mice [19]. Taken together, these animal
model studies further support a role for HBZ in the T-lym-
phocyte proliferation.
The role of HBZ in HTLV-1 pathogenesis
The HBZ gene is expressed in ATL cells from all patients
and its expression level is correlated with provirus load. In
many ATL cases, HBZ  is the only viral gene that is
expressed. Furthermore, the HBZ gene has growth-pro-
moting activity in vivo and in vitro, indicating that the HBZ
gene likely is critical for ATL cells even at the late stage of
leukemogenesis. There are two scenarios, not necessarily
mutually exclusive, for the requirement of the HBZ gene
in ATL induction. First, at the early stage of infection, both
tax and HBZ genes are needed for the proliferation and
maintenance of infected cells. Since Tax is the major target
of CTL, cells without or with low Tax expression can evade
immune surveillance. The finding that defective provi-
ruses without a 5' LTR are generated after integration sup-
port this scenario. Second, only the HBZ gene is essential
for maintaining oncogenesis while Tax contributes to the
process that initiates and promotes cell growth with sub-
sequently causes genetic instability. In either scenario, the
HBZ gene is critical for oncogenesis by HTLV-1. In addi-
tion, since HBZ promotes proliferation of HTLV-1
infected T-cells, increased HTLV-1 infected cells should be
implicated in pathogenesis of HAM/TSP. Since the HBZRetrovirology 2009, 6:71 http://www.retrovirology.com/content/6/1/71
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gene is the sole viral gene expressed in ATL cells, it is an
ideal target for therapy of not only ATL, but also HAM/
TSP.
Perspectives
Since the discovery of HTLV-1, there have been significant
advances to our understanding of virus biology, immu-
nology, and oncogenesis. However, the precise mecha-
nism of oncogenesis by HTLV-1 remains to be
determined. Recent intensive research on the antisense
HBZ gene has yielded new important insight into the dis-
ease process: the HBZ gene appears to be the only viral
gene that is constantly expressed in HTLV-1-infected cells
and ATL cells. The data is consistent with HBZ playing a
critical role in the proliferation of newly infected cells as
well as in transformed ATL. Therefore, therapy targeted
against HBZ might provide a promising new approach to
the treatment of ATL as well as HAM/TSP. Some aspects of
the HTLV-1 antisense transcript function may be con-
served in other retroviruses since similar antisense RNAs
have also been reported for HIV-1 [41].
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
MM and PLG shared equally in the research, writing, and
editing of the manuscript. Both authors read and
approved the final manuscript.
Acknowledgements
We thank Kathleen Hayes-Ozello and Kuan-Teh Jeang for editorial com-
ments on the manuscript. This work was supported by a grant from the 
National Institutes of Health (CA077556) to PLG.
References
1. Takatsuki K: Discovery of adult T-cell leukemia.  Retrovirology
2005, 2:16.
2. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC:
Detection and isolation of type C retrovirus particles from
fresh and cultured lymphocytes of a patient with cutaneous
T-cell lymphoma.  Proc Natl Acad Sci USA 1980, 77:7415-7419.
3. Hinuma Y, Nagata K, Hanaoka M, Nakai M, Matsumoto T, Kinoshita
K-I, Shirakawa S, Miyoshi I: Adult T-cell leukemia: Antigen in an
ATL cell line and detection of antibodies to the antigen in
human sera.  Proc Natl Acad Sci USA 1981, 78:6476-6480.
4. Takeda S, Maeda M, Morikawa S, Taniguchi Y, Yasunaga J, Nosaka K,
Tanaka Y, Matsuoka M: Genetic and epigenetic inactivation of
tax gene in adult T-cell leukemia cells.  Int J Cancer 2004,
109:559-567.
5. Satou Y, Yasunaga J, Yoshida M, Matsuoka M: HTLV-I basic leucine
zipper factor gene mRNA supports proliferation of adult T
cell leukemia cells.  Proc Natl Acad Sci USA 2006, 103:720-725.
6. Yoshida M: Multiple viral strategies of HTLV-1 for dysregula-
tion of cell growth control.  Annu Rev Immunol 2001, 19:475-496.
7. Boxus M, Twizere JC, Legros S, Dewulf JF, Kettmann R, Willems L:
The HTLV-1 Tax interactome.  Retrovirology 2008, 5:76.
8. Furukawa Y, Kubota R, Tara M, Izumo S, Osame M: Existence of
escape mutant in HTLV-I tax during the development of
adult T-cell leukemia.  Blood 2001, 97:987-993.
9. Tamiya S, Matsuoka M, Etoh K, Watanabe T, Kamihira S, Yamaguchi
K, Takatsuki K: Two types of defective human T-lymphotropic
virus type I provirus in adult T-cell leukemia.  Blood 1996,
88:3065-3073.
10. Miyazaki M, Yasunaga J, Taniguchi Y, Tamiya S, Nakahata T, Matsuoka
M: Preferential selection of human T-cell leukemia virus type
1 provirus lacking the 5' long terminal repeat during onco-
genesis.  J Virol 2007, 81:5714-5723.
11. Koiwa T, Hamano-Usami A, Ishida T, Okayama A, Yamaguchi K,
Kamihira S, Watanabe T: 5'-long terminal repeat-selective CpG
methylation of latent human T-cell leukemia virus type 1
provirus in vitro and in vivo.  J Virol 2002, 76:9389-9397.
12. Taniguchi Y, Nosaka K, Yasunaga J, Maeda M, Mueller N, Okayama A,
Matsuoka M: Silencing of human T-cell leukemia virus type I
gene transcription by epigenetic mechanisms.  Retrovirology
2005, 2:64.
13. Kannagi M, Harada S, Maruyama I, Inoko H, Igarashi H, Kuwashima G,
Sato S, Morita M, Kidokoro M, Sugimoto M, et al.: Predominant
recognition of human T cell leukemia virus type I (HTLV-I)
pX gene products by human CD8+ cytotoxic T cells directed
against HTLV-I-infected cells.  Int Immunol 1991, 3:761-767.
14. Cavanagh M-H, Landry S, Audet B, Arpin-Andre C, Hivin P, Pare M-E,
Thete J, Wattel E, Marriott S, Mesnard J-M, Barbeau B: HTLV-I anti-
sense transcripts initiating in the 3' LTR are alternatively
spliced and polyadenylated.  Retrovirology 2006, 3:15.
15. Murata K, Hayashibara T, Sugahara K, Uemura A, Yamaguchi T, Har-
asawa H, Hasegawa H, Tsuruda K, Okazaki T, Koji T, et al.: A novel
alternative splicing isoform of human T-cell leukemia virus
type 1 bZIP factor (HBZ-SI) targets distinct subnuclear
localization.  J Virol 2006, 80:2495-2505.
16. Yoshida M, Satou Y, Yasunaga J, Fujisawa J, Matsuoka M: Transcrip-
tional control of spliced and unspliced human T-cell leuke-
mia virus type 1 bZIP factor (HBZ) gene.  J Virol 2008,
82:9359-9368.
17. Usui T, Yanagihara K, Tsukasaki K, Murata K, Hasegawa H, Yamada Y,
Kamihira S: Characteristic expression of HTLV-1 basic zipper
factor (HBZ) transcripts in HTLV-1 provirus-positive cells.
Retrovirology 2008, 5:34.
18. Saito M, Matsuzaki T, Satou Y, Yasunaga J, Saito K, Arimura K, Mat-
suoka M, Ohara Y: In vivo expression of the HBZ gene of
HTLV-1 correlates with proviral load, inflammatory mark-
ers and disease severity in HTLV-1 associated myelopathy/
tropical spastic paraparesis (HAM/TSP).  Retrovirology 2009,
6:19.
19. Arnold J, Zimmerman B, Li M, Lairmore MD, Green PL: Human T-
cell Leukemia Virus Type-1 Antisense-encoded Gene, Hbz,
Promotes T Lymphocyte Proliferation.  Blood 2008,
112:3788-97.
20. Larocca D, Chao LA, Seto MH, Brunck TK: Human T-cell leuke-
mia virus minus strand transcription in infected cells.  Biochem
Biophys Res Commun 1989, 163:1006-1013.
21. Gaudray G, Gachon F, Basbous J, Biard-Piechaczyk M, Devaux C,
Mesnard J: The complementary strand of the human T-cell
leukemia virus type 1 RNA genome encodes a bZIP tran-
scription factor that down-regulates viral transcription.  J
Virol 2002, 76:12813-12822.
22. Landry S, Halin M, Vargas A, Lemasson I, Mesnard JM, Barbeau B:
Upregulation of human T-cell leukemia virus type 1 anti-
sense transcription by the viral tax protein.  J Virol 2009,
83:2048-2054.
23. Hivin P, Frederic M, Arpin-Andre C, Basbous J, Gay B, Thebault S,
Mesnard JM: Nuclear localization of HTLV-I bZIP factor
(HBZ) is mediated by three distinct motifs.  J Cell Sci 2005,
118:1355-1362.
24. Basbous J, Arpin C, Gaudray G, Piechaczyk M, Devaux C, Mesnard J:
HBZ factor of HTLV-1 dimerizes with transcription factors
JunB and c-Jun and modulates their transcriptional activity.
J Biol Chem 2003, 278:43620-43627.
25. Thebault S, Basbous J, Hivin P, Devaux C, Mesnard JM: HBZ inter-
acts with JunD and stimulates its transcriptional activity.
FEBS Lett 2004, 562:165-170.
26. Zhao T, Yasunaga J, Satou Y, Nakao M, Takahashi M, Fujii M, Matsuoka
M: Human T-cell leukemia virus type 1 bZIP factor selec-
tively suppresses the classical pathway of NF-kappaB.  Blood
2009, 113:2755-2764.
27. Hivin P, Basbous J, Raymond F, Henaff D, Arpin-Andre C, Robert-
Hebmann V, Barbeau B, Mesnard JM: The HBZ-SP1 isoform ofPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Retrovirology 2009, 6:71 http://www.retrovirology.com/content/6/1/71
Page 8 of 8
(page number not for citation purposes)
human T-cell leukemia virus type I represses JunB activity by
sequestration into nuclear bodies.  Retrovirology 2007, 4:14.
28. Isono O, Ohshima T, Saeki Y, Matsumoto J, Hijikata M, Tanaka K, Shi-
motohno K: Human T-cell leukemia virus type 1 HBZ protein
bypasses the targeting function of ubiquitination.  J Biol Chem
2008, 283:34273-34282.
29. Arnold J, Yamamoto B, Li M, Phipps AJ, Younis I, Lairmore MD, Green
PL:  Enhancement of infectivity and persistence in vivo by
HBZ, a natural antisense coded protein of HTLV-1.  Blood
2006, 107:3976-3982.
30. Lemasson I, Lewis MR, Polakowski N, Hivin P, Cavanagh MH, The-
bault S, Barbeau B, Nyborg JK, Mesnard JM: Human T-cell leuke-
mia virus type 1 (HTLV-1) bZIP protein interacts with the
cellular transcription factor CREB to inhibit HTLV-1 tran-
scription.  J Virol 2007, 81:1543-1553.
31. Clerc I, Polakowski N, Andre-Arpin C, Cook P, Barbeau B, Mesnard
JM, Lemasson I: An interaction between the human T cell
leukemia virus type 1 basic leucine zipper factor (HBZ) and
the KIX domain of p300/CBP contributes to the down-regu-
lation of tax-dependent viral transcription by HBZ.  J Biol
Chem 2008, 283:23903-23913.
32. Matsumoto J, Ohshima T, Isono O, Shimotohno K: HTLV-1 HBZ
suppresses AP-1 activity by impairing both the DNA-binding
ability and the stability of c-Jun protein.  Oncogene 2005,
24:1001-1010.
33. Kuhlmann AS, Villaudy J, Gazzolo L, Castellazzi M, Mesnard JM, Duc
Dodon M: HTLV-1 HBZ cooperates with JunD to enhance
transcription of the human telomerase reverse transcriptase
gene (hTERT).  Retrovirology 2007, 4:92.
34. Li M, Green PL: Detection and quantitation of HTLV-1 and
HTLV-2 mRNA species by real-time RT-PCR.  J Virol Methods
2007, 142:159-168.
35. Li M, Kesic M, Yin H, Lianbo Y, Green P: Kinetic analysis of
Human T-cell leukemia virus type 1 gene expression in cell
culture and infected animals.  J Virol 2009, 83:3788-3797.
36. Morrison TE, Kenney SC: BZLF1, an Epstein-Barr virus imme-
diate-early protein, induces p65 nuclear translocation while
inhibiting p65 transcriptional function.  Virology 2004,
328:219-232.
37. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ, Van Wier
S, Tiedemann R, Shi CX, Sebag M, et al.: Promiscuous mutations
activate the noncanonical NF-kappaB pathway in multiple
myeloma.  Cancer Cell 2007, 12:131-144.
38. Bernal-Mizrachi L, Lovly CM, Ratner L: The role of NF-{kappa}B-
1 and NF-{kappa}B-2-mediated resistance to apoptosis in
lymphomas.  Proc Natl Acad Sci USA 2006, 103:9220-9225.
39. Higuchi M, Tsubata C, Kondo R, Yoshida S, Takahashi M, Oie M, Tan-
aka Y, Mahieux R, Matsuoka M, Fujii M: Cooperation of NF-
kappaB2/p100 activation and the PDZ domain binding motif
signal in human T-cell leukemia virus type 1 (HTLV-1) Tax1
but not HTLV-2 Tax2 is crucial for interleukin-2-independ-
ent growth transformation of a T-cell line.  J Virol 2007,
81:11900-11907.
40. Yan P, Fu J, Qu Z, Li S, Tanaka T, Grusby MJ, Xiao G: PDLIM2 sup-
presses human T-cell leukemia virus type I Tax-mediated
tumorigenesis by targeting Tax into the nuclear matrix for
proteasomal degradation.  Blood 2009, 113:4370-4380.
41. Landry S, Halin M, Lefort S, Audet B, Vaquero C, Mesnard JM, Bar-
beau B: Detection, characterization and regulation of anti-
sense transcripts in HIV-1.  Retrovirology 2007, 4:71.